[Clinical effects of 1 alpha-hydroxycholecalciferol (alpha-D3) in hypoparathyroidism--comparison with dihydrotachysterol (DHT2)--multi-institutional double blind studies]. 1979

T Fujita, and Y Furukawa, and T Son, and E Ogata, and Y Fujimoto

UI MeSH Term Description Entries
D007011 Hypoparathyroidism A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone. Idiopathic Hypoparathyroidism,Hypoparathyroidism, Idiopathic
D008297 Male Males
D002762 Cholecalciferol Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24. Vitamin D 3,(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol,Calciol,Cholecalciferols,Vitamin D3
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004097 Dihydrotachysterol A VITAMIN D that can be regarded as a reduction product of vitamin D2. AT 10,AT-10,Calcamine,Dihydrotachysterin,Tachystin,AT10
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

T Fujita, and Y Furukawa, and T Son, and E Ogata, and Y Fujimoto
August 1977, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
T Fujita, and Y Furukawa, and T Son, and E Ogata, and Y Fujimoto
June 1978, Polskie Archiwum Medycyny Wewnetrznej,
T Fujita, and Y Furukawa, and T Son, and E Ogata, and Y Fujimoto
October 1978, Horumon to rinsho. Clinical endocrinology,
T Fujita, and Y Furukawa, and T Son, and E Ogata, and Y Fujimoto
August 1974, Lancet (London, England),
T Fujita, and Y Furukawa, and T Son, and E Ogata, and Y Fujimoto
June 1990, Zhonghua nei ke za zhi,
T Fujita, and Y Furukawa, and T Son, and E Ogata, and Y Fujimoto
January 1982, Journal of neurology, neurosurgery, and psychiatry,
T Fujita, and Y Furukawa, and T Son, and E Ogata, and Y Fujimoto
January 1974, Problemy endokrinologii,
T Fujita, and Y Furukawa, and T Son, and E Ogata, and Y Fujimoto
February 1972, Nihon rinsho. Japanese journal of clinical medicine,
T Fujita, and Y Furukawa, and T Son, and E Ogata, and Y Fujimoto
March 2014, Current vascular pharmacology,
Copied contents to your clipboard!